Galectin Therapeutics to Present Clinical Data at The Liver Meeting® 2017 Demonstrating the Ability of Non-Invasive Test to Identify Clinically Significant Portal Hypertension in Patients with Compensated NASH Cirrhosis
Based on previous studies that showed a strong correlation between hepatic venous pressure gradient (HVPG) and liver stiffness measurement (LSM) as a valid predictor of the development of complications from cirrhosis, investigators examined the potential utility of VCTE to measure LSM in patients with NASH cirrhosis as well as the ability to detect clinically significant portal hypertension (CSPH) in this patient population.
Vibration-controlled transient elastography is a non-invasive tool that measures the liver stiffness measurement (LSM) reliably. Several studies have reported a good correlation between LSM and HPVG and its ability to detect CPSH.
"Measuring HVPG is an invasive and expensive procedure that requires special expertise, therefore, having a non-invasive diagnostic tool that predicts HPVG is very valuable in the management of cirrhosis," said
Details for poster presentation at The Liver Meeting:
Poster Session I
"Liver Stiffness Measured By Vibration Controlled Transient Elastography Is An Excellent Surrogate for Identifying Clinically Significant Portal Hypertension In Patients With Compensated NASH Cirrhosis,"
About Galectin Therapeutics
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver and skin diseases and cancer. Galectin's lead drug (GR-MD-02) is a carbohydrate-based drug that inhibits the galectin-3 protein that is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH related fibrosis. This is the most common liver disease and one of the largest drug development opportunities available today. Additional development programs are for treatment of severe atopic dermatitis, moderate-to-severe plaque psoriasis, and in combination immunotherapy for advanced melanoma and other malignancies. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeutics.com.
News Provided by Acquire Media